Thus, sorafenib inhibits the RAF-MEK-ERK/MAPK pathway to suppress tumor proliferation and is also a highly effective inhibitor of the pro-angiogenic VEGFs and PDGFR to suppress the microvasculature of tumors [1–4]. Here, MAP2K7 is linked to neoplasm.